scholarly journals Acquired Resistance to Tamoxifen Is Associated with Loss of the Type I Insulin-like Growth Factor Receptor: Implications for Breast Cancer Treatment

2012 ◽  
Vol 72 (13) ◽  
pp. 3372-3380 ◽  
Author(s):  
Dedra H. Fagan ◽  
Ryan R. Uselman ◽  
Deepali Sachdev ◽  
Douglas Yee
Keyword(s):  
Breast Cancer ◽  
Growth Factor ◽  
Cancer Treatment ◽  
Acquired Resistance ◽  
Growth Factor Receptor ◽  
Breast Cancer Treatment ◽  
Type I ◽  
Insulin Like Growth Factor

scholarly journals 40 YEARS OF IGF1: Anti-insulin-like growth factor therapy in breast cancer

2018 ◽  
Vol 61 (1) ◽  
pp. T61-T68 ◽  
Author(s):  
Douglas Yee
Keyword(s):  
Breast Cancer ◽  
Clinical Trials ◽  
Growth Factor ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Population Data ◽  
Type I ◽  
Insulin Like Growth Factor ◽  
Growth And Survival ◽  
Cancer Multiple

Early preclinical and population data suggested a role for the type I insulin-like growth factor receptor (IGF1R) in the regulation of breast cancer growth and survival. To target this pathway, multiple monoclonal antibodies and tyrosine kinase inhibitors were developed and tested in clinical trials. While some of the early clinical trials suggested a benefit for these drugs, none of the attempts showed improved outcomes when compared to conventional therapy. This failure of the IGF1R inhibitors was pronounced in breast cancer; multiple trials testing IGF1R inhibition in estrogen receptor-positive breast cancer were conducted, none showed benefit. This review will evaluate the rationale for IGF1R inhibition, discuss results of the clinical trials and suggest a path forward.

Sign in / Sign up

Export Citation Format

Share Document